Skip To Main Content
Jim Hickey on Muck Rack

Jim Hickey

New England
As seen in: International Business Times (U.S.), GlobeNewswire, WRAL-TV (Raleigh, NC), KTLA-TV (Los Angeles, CA), Morningstar, KDVR-TV (Denver, CO), WFLA-TV (Tampa, FL), StreetInsider, ADVFN, WDAF-TV (Kansas City, MO) and
Sharing cool info on bass and bass fishing

Get in touch with Jim

Contact Jim, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Articles

Spherix Global Insights Finds One-Third of Treated MASH Patients Remain Inadequately Controlled Even as Prescription Use Expands

|
By Jim Hickey
| FinancialContent
Published at August 20th 2026, 11:04 AM EDT via GlobeNewswire ⓘ This article is third-party content and does not represent the views of this site. We make no guarantees regarding its accuracy or completeness. Exton, PA, Aug. 20, 2026 (GLOBE NEWSWIRE) -- The treatment landscape for metabolic dysfunction-associated steatohepatitis (MASH) is expanding as prescription therapy becomes integrated into routine patient management.
Open in Who Shared Issue with article?

Spherix Global Insights Finds One-Third of Treated MASH Patients Remain Inadequately Controlled Even as Prescription Use Expands

|
By Jim Hickey
| WREG-TV (Memphis, TN) Verified
Exton, PA, Aug. 20, 2026 (GLOBE NEWSWIRE) -- The treatment landscape for metabolic dysfunction-associated steatohepatitis (MASH) is expanding as prescription therapy becomes integrated into routine patient management. Despite this progress, substantial unmet needs persist, with many treated patients experiencing suboptimal outcomes or requiring a treatment change, raising questions about how physicians will manage inadequate response as the therapeutic landscape expands.
Open in Who Shared Issue with article?

Spherix Global Insights Finds One-Third of Treated MASH Patients Remain Inadequately Controlled Even as Prescription Use Expands

|
By Jim Hickey
| WCBD-TV (Mount Pleasant, SC) Verified
Spherix Global Insights Finds One-Third of Treated MASH Patients Remain Inadequately Controlled Even as Prescription Use Expands Physicians favor longer trials and therapy augmentation, while tailored combination use signals greater complexity once new options enter the market. News provided by Spherix Global Insights Aug 20, 2026, 11:04 AM ET Exton, PA, Aug.
Open in Who Shared View Duplicates (23) Issue with article?
See all 1,050 licensed articles (1,052 Total)